[{"orgOrder":0,"company":"Affibody","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"ABY-035","moa":"IL-17","graph1":"Immunology","graph2":"Phase II","graph3":"Affibody","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.23000000000000001,"dosageForm":"","sponsorNew":"Affibody \/ Inmagene Biopharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Affibody \/ Inmagene Biopharmaceuticals"},{"orgOrder":0,"company":"Affibody","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"ABY-035","moa":"IL-17A","graph1":"Dermatology","graph2":"Phase II","graph3":"Affibody","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Affibody \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Affibody \/ Not Applicable"},{"orgOrder":0,"company":"Affibody","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"ABY-035","moa":"IL-17A","graph1":"Immunology","graph2":"Phase II","graph3":"Affibody","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Affibody \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Affibody \/ Not Applicable"},{"orgOrder":0,"company":"Affibody","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Izokibep","moa":"IL-17 A receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Affibody","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Affibody \/ Affibody AB","highestDevelopmentStatusID":"8","companyTruncated":"Affibody \/ Affibody AB"},{"orgOrder":0,"company":"Affibody","sponsor":"Acelyrin","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Izokibep","moa":"IL-17A","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Affibody","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Affibody \/ Affibody AB","highestDevelopmentStatusID":"9","companyTruncated":"Affibody \/ Affibody AB"},{"orgOrder":0,"company":"Affibody","sponsor":"Chiesi Group","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Discovery","graph3":"Affibody","amount2":0.20999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.20999999999999999,"dosageForm":"","sponsorNew":"Affibody \/ Chiesi Group","highestDevelopmentStatusID":"2","companyTruncated":"Affibody \/ Chiesi Group"}]